7 Recruiting Melanoma Stage III Phase 2 Clinical Trials
Active phase 2 studies for melanoma stage iii enrolling across the USA. Verify eligibility and contact site coordinators.
All Melanoma Stage III studiesPhase 2 Studies for Melanoma Stage III
🔵 Active, Not Recruiting Phase2
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
📍 Duke Cancer Institute — Durham, North Carolina
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
📍 Georgetown University Medical Center — Washington D.C., District of Columbia
View Study & Checklist ➔ 🟢 Recruiting Phase2
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
📍 UC San Diego Moores Cancer Center — La Jolla, California
View Study & Checklist ➔ 🟢 Recruiting Phase2
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔ 🟢 Recruiting Phase2
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔ 🟢 Recruiting Phase2
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔